Literature DB >> 20876623

Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.

Emilia Siikala1, Riina Rautemaa, Malcolm Richardson, Harri Saxen, Paul Bowyer, Dominique Sanglard.   

Abstract

OBJECTIVES: Patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I) suffer from chronic candidosis caused mainly by Candida albicans, and repeated courses of azole antifungals have led to the development of resistance in the APECED patient population in Finland. The aim of our study was to address whether the patients are persistently colonized with the same or genetically closely related strains, whether epidemic strains are present and which molecular mechanisms account for azole resistance.
METHODS: Sets of C. albicans (n = 19) isolates from nine APECED patients reported with decreased susceptibility to fluconazole isolated up to 9 years apart were included. The strains were typed by multilocus sequence typing. CDR1/2, MDR1 and ERG11 mRNA expression was analysed by northern blotting and Cdr1, Cdr2 and Mdr1 protein expression by western blotting, and TAC1 and ERG11 genes were sequenced.
RESULTS: All seven patients with multiple C. albicans isolates analysed were persistently colonized with the same or a genetically closely related strain for a mean of 5 years. All patients were colonized with different strains and no epidemic strains were found. The major molecular mechanisms behind the azole resistance were mutations in TAC1 contributing to overexpression of CDR1 and CDR2. Six new TAC1 mutations were found, one of which (N740S) is likely to be a gain-of-function mutation. Most isolates were found to have gained multiple TAC1 and ERG11 point mutations.
CONCLUSIONS: Despite clinically successful treatment leading to relief of symptoms, colonization by C. albicans strains is persistent within APECED patients. Microevolution and point mutations occur within strains, leading to the development of azole-resistant isolates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876623     DOI: 10.1093/jac/dkq354

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

1.  Azole antifungal resistance today: focus on Aspergillus.

Authors:  Paul Bowyer; Caroline B Moore; Riina Rautemaa; David W Denning; Malcolm D Richardson
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

Review 2.  Mechanisms of Antifungal Drug Resistance.

Authors:  Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

3.  Comparison of the Antibacterial Properties of Three Mouthwashes Containing Chlorhexidine Against Oral Microbial Plaques: An in vitro Study.

Authors:  Hojatollah Yousefimanesh; Mansour Amin; Maryam Robati; Hamed Goodarzi; Masumeh Otoufi
Journal:  Jundishapur J Microbiol       Date:  2015-02-20       Impact factor: 0.747

Review 4.  Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans.

Authors:  Andrew T Nishimoto; Cheshta Sharma; P David Rogers
Journal:  J Antimicrob Chemother       Date:  2020-02-01       Impact factor: 5.790

5.  Microbiological screening of Irish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy reveals persistence of Candida albicans strains, gradual reduction in susceptibility to azoles, and incidences of clinical signs of oral candidiasis without culture evidence.

Authors:  Brenda A McManus; Eleanor McGovern; Gary P Moran; Claire M Healy; June Nunn; Pádraig Fleming; Colm Costigan; Derek J Sullivan; David C Coleman
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

6.  Update on Antifungal Drug Resistance.

Authors:  David S Perlin; Erika Shor; Yanan Zhao
Journal:  Curr Clin Microbiol Rep       Date:  2015-06-01

7.  Editorial: Antifungal Drug Discovery: New Theories and New Therapies.

Authors:  Chaminda J Seneviratne; Edvaldo A R Rosa
Journal:  Front Microbiol       Date:  2016-05-23       Impact factor: 5.640

Review 8.  Potential Use of Phenolic Acids as Anti-Candida Agents: A Review.

Authors:  Guilherme R Teodoro; Kassapa Ellepola; Chaminda J Seneviratne; Cristiane Y Koga-Ito
Journal:  Front Microbiol       Date:  2015-12-21       Impact factor: 5.640

9.  In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.

Authors:  Sarah Sze Wah Wong; Richard Yi Tsun Kao; Kwok Yong Yuen; Yu Wang; Dan Yang; Lakshman Perera Samaranayake; Chaminda Jayampath Seneviratne
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

Review 10.  Clinical Appearance of Oral Candida Infection and Therapeutic Strategies.

Authors:  Shankargouda Patil; Roopa S Rao; Barnali Majumdar; Sukumaran Anil
Journal:  Front Microbiol       Date:  2015-12-17       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.